ArticleCytotechnology2021
miR-17-5p accelerates cervical cancer cells migration and invasion via the TIMP2/MMPs signaling cascade.
Article in Cytotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Upregulation of a MicroRNA Signature Involving miR-17-5p, miR-26b-5p, miR-106a-5p, and miR-146a-5p During Cervical Epithelial Transformation.Epigenomes · 2025Article
- AAAGUGC Seed-Containing miRNAs: Master Regulators of Cancer Pathways and Therapeutic Resistance.MicroRNA (Shariqah, United Arab Emirates) · 2025Review
- Construction of an exosome-associated miRNA-mRNA regulatory network and validation ofTranslational cancer research · 2024Article
- miR-17-5p slows progression of hepatocellular carcinoma by downregulating TGFβR2.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Expression and clinical significance of miR-17-5p in tumor tissues of patients with colorectal cancer.Journal of gastrointestinal oncology · 2022Article
- Comprehensive bioinformatics analysis forTranslational cancer research · 2022Article
- Article
- Comprehensive Pan-Cancer Analysis of the Prognostic and Immunological Roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C Axis.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) is a common gynecological tumor, ranking second in the female reproductive system tumor. The work aims to study the function of miR-17-5p in the occurrence and pathogenesis of CC. We collected 36 cases of CC tissues for clinical analysis, and two CC cell lines (C33a and HCC94) were obtained for cellular analysis. As expected, the up-regulated miR-17-5p and down-regulated TIMP2 were detected in CC tissues and cell lines by RT-qPCR, in contrast with their normal counterparts. Then, overexpression of miR-17-5p significantly increased the CC cells viability and colonies formation abilities. Moreover, the Transwell analysis revealed that miR-17-5p promoted the capability of invasion and migration. Meanwhile, the expression levels of MMP2 and MMP9 was inhibited by the inhibition of miR-17-5p. The luciferase analysis demonstrated that TIMP2 was the target of miR-17-5p. In addition, cell proliferation, invasion and migration in HCC94 cells were repressed by silencing miR-17-5p, which were reversed by TIMP2 knockdown. In summary, all results indicated that miR-17-5p targeted TIMP2 to modulate CC cells' proliferation, invasion and migration through MMPs signaling pathway; and the miR-17-5p/TIMP2/MMPs signaling pathway had the potential to become a therapeutic target of CC for clinical utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.